KADIMASTEM
Kadimastem is a regenerative medicine company focused on the industrial development and commercialization of stem cell-based therapeutics, primarily for diabetes and neurodegenerative disorders. The company’s proprietary technologies and know-how enable the differentiation of stem cells into insulin secreting beta cells as well as a range of neural cells, including Oligodendrocytes and Astrocytes. Based on its differentiation technologies, the company advances two therapeutic programs focused... on diabetes mellitus and ALS, where stem cells are differentiated into beta cells for the diabetes program and astrocytes are differentiated into beta cells for the ALS program, with the goal of implanting them into patients, and affecting diseases progression. The company’s technology is designed to screen compounds automatically and quantify the readouts using a cell-based High Content Screening (HCS) system. Kadimastem partners with pharmaceutical companies to screen potential drug compounds on its stem-cell derived cells. It produces a number of human cell and tissue systems that constitute screening platforms to search for agonists or antagonists of specific biological processes, with the aim of developing safe drugs. Kadimastem is based in Nes Ziona, Israel.
KADIMASTEM
Social Links:
Industry:
Biotechnology Therapeutics
Founded:
2009-01-01
Address:
Ness Ziona, HaMerkaz, Israel
Country:
Israel
Website Url:
http://www.kadimastem.com
Total Employee:
11+
Status:
Active
Contact:
97297289100698
Email Addresses:
[email protected]
Total Funding:
13.31 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Apple Mobile Web Clips Icon Content Delivery Network Microsoft Exchange Online Organization Schema Office 365 Mail Person Schema
Similar Organizations
Aclaris Therapeutics
Aclaris Therapeutics is a specialty pharmaceutical company engaged in developing dermatologic therapies.
Crinetics Pharmaceuticals
Crinetics is a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics.
FORMA Therapeutics
FORMA Therapeutics is a biopharmaceutical company focused on the discovery, development, and commercialization of transformative medicines.
immatics biotechnologies
immatics is a biopharmaceutical company focused on the development of immunotherapeutic substances for cancer therapy.
Kamada
Kamada is a biopharmaceutical company engaged in developing, producing and marketing of specialty life-saving therapeutics, using a unique
Rebirthel
Rebirthel is a biotech company, focused on the Development and operationalization of cell-based cancer immunotherapies.
Regulus Therapeutics
Regulus Therapeutics is a clinical stage biopharmaceutical company focused on the development and discovery of microRNA therapeutics.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Ilex Medical
Ilex Medical investment in Post-IPO Equity - Kadimastem
Michel Revel
Michel Revel investment in Post-IPO Equity - Kadimastem
Julien Ruggieri
Julien Ruggieri investment in Post-IPO Equity - Kadimastem
Clover Wolf Capital
Clover Wolf Capital investment in Post-IPO Equity - Kadimastem
Alpha Capital Anstalt
Alpha Capital Anstalt investment in Post-IPO Equity - Kadimastem
Altshuler Shaham
Altshuler Shaham investment in Post-IPO Equity - Kadimastem
Official Site Inspections
http://www.kadimastem.com Semrush global rank: 5.85 M Semrush visits lastest month: 1.42 K
- Host name: unalocated.63.wixsite.com
- IP address: 185.230.63.171
- Location: Ashburn United States
- Latitude: 39.018
- Longitude: -77.539
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20147
More informations about "Kadimastem"
Kadimastem - Crunchbase Company Profile & Funding
Kadimastem is a regenerative medicine company focused on the industrial development and commercialization of stem cell-based therapeutics, primarily for diabetes and …See details»
Leadership Team | Kadimastem
Following the completion of his thesis, Dr. Molakandov joined Kadimastem. He leads the team that is developing cell-therapy for diabetes using Pluripotent Stem Cells as the cell source. His team has dedicated the last few years in …See details»
Kadimastem Ltd. - LinkedIn
Kadimastem (TASE:KDST) A clinical stage biotech company introducing a cutting-edge TECHNOLOGY PLATFORM for the Development, Manufacturing, and Bio-Banking of functional human cells, providing OFF ...See details»
Kadimastem Org Chart + Executive Team - The Official Board
Organizational Chart of Kadimastem. Kadimastem Org Chart www.kadimastem.com +972 737 971 600; Add an executive. Kadimastem News . Anything missing? We search for you. Print or …See details»
Kadimastem Calls for a Special General Meeting of Shareholders to ...
Jan 16, 2025 Kadimastem Approaches Final Steps for Securing Merger CompletionZURICH, SWITZERLAND and NESS ZIONA, ISRAEL— January 16th 2025 — NLS Pharmaceutics Ltd. …See details»
Kadimastem Company Profile | Management and Employees List
Kadimastem was founded by Professor Michel Revel, CSO of the Company and Professor Emeritus of Molecular Genetics at the Weizmann Institute of Science. Professor Revel …See details»
Kadimastem - Devex
Kadimastem (TASE: KDST) is a bio-pharmaceutical company that develops industrial regenerative medicine therapies based on differentiated cells derived from Human Embryonic …See details»
Kadimastem Company Profile - Craft
Oct 29, 2024 Kadimastem is a biopharmaceutical company that develops industrial regenerative medicine therapies based on differentiated cells derived from human embryonic stem cells …See details»
Kadimastem - VentureRadar
Kadimastem (TASE: KDST) is a biopharmaceutical company that develops industrial regenerative medicine therapies based on differentiated cells derived from Human Embryonic Stem Cells …See details»
Kadimastem - Contacts, Employees, Board Members, Advisors
Kadimastem is a regenerative medicine company focused on the industrial development and commercialization of stem cell-based therapeutics. New. Resources. Advanced Search. Start …See details»
Kadimastem - Products, Competitors, Financials, Employees, …
Kadimastem. 's Products & Differentiators. AstroRx® Clinical grade human astrocytes (the nervous system supporting cells) for the treatment of ALS and other neurodegenerative …See details»
Kadimastem Ltd. - Drug pipelines, Patents, Clinical trials - Synapse
Explore Kadimastem Ltd. with its drug pipeline, therapeutic area, technology platform, 1 clinical trial, 19 news, and 6 literature, Disease Domain:Immune System Diseases, Endocrinology and …See details»
Kadimastem - Funding, Financials, Valuation & Investors
Kadimastem is a regenerative medicine company focused on the industrial development and commercialization of stem cell-based therapeutics. Search Crunchbase. ... How much funding …See details»
Kadimastem | YEDA Technology Transfer
Kadimastem develops industrial regenerative medicine therapies based on differentiated cells derived from human embryonic stem cells to treat diseases such as amyotrophic lateral …See details»
Technology | Kadimastem
The article describes the safety and efficacy results of AstroRx®; Kadimastem's cell therapy product in its first in-human phase I/IIa clinical trial in 10 ALS patients conducted in Israel from …See details»
Kadimastem gets shareholder backing for NLS merger
Jan 31, 2025 Cash is tight—the merger requires NLS and Kadimastem to have just $600,000 and $3.5 million, respectively, at closing—and the Israeli biotech wants to start a phase 2a trial …See details»
Company Pipeline - Kadimastem new
Kadimastem's product IsletRx contains pancreatic islet cells which produce and secrete insulin and glucagon in response to blood glucose levels. IsletRx is produced utilizing proprietary …See details»
Kadimastem: Stem Cell-based Cell Therapy: The Future of Healthcare
Kadimastem has the ability to store large quantities of cell products for wider distribution. This ability will also help to facilitate the advanced stages of clinical and marketing trials. …See details»
Investors and Media | Kadimastem
Mar 31, 2025 NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce the Initial Closing of $500,000 of the Previously Announced $1 Million Fundraising by NLS Following its …See details»